ALHC Stock Tumbles After ‘Don’t Poke the Bear’ Silence On Star Ratings — CLOV Falls With It
Alignment Healthcare (ALHC) shares dropped 22% after executives declined to discuss next year's quality bonus and noted higher-than-expected hospital bills. CEO John Kao cited CMS sensitivity about commenting on Plan Preview 2. Clover Health (CLOV) also fell 9%. ALHC's CFO mentioned institutional cost headwinds but expects them to ease by 2027. Guidance remained unchanged.
How this was made
The 30-second read
Why it matters
The executive silence on star rating outlook heightened investor uncertainty, prompting a sharp sell-off.
Market read
The stock's 22% drop underscores sensitivity to regulatory guidance on star ratings.
What to watch
Potential upcoming software upgrades could resolve claim processing delays.
Background
Alignment Healthcare is a Medicare Advantage insurer whose star ratings affect federal payments.
Ticker impact
Alignment Healthcare shares fell 22% after executives refused to discuss Medicare Advantage star ratings at a Baird conference.
Further downside risk if star rating concerns persist.
The abrupt silence on Plan Preview 2 and existing cost headwinds suggest continued pressure on the stock.
Market effects
Medicare Advantage providers may face heightened scrutiny on star ratings.
U.S. healthcare sector sees increased volatility.
Limited to U.S. market participants.
Counterpoint
The stock may be oversold; a clear path to improved star ratings could trigger a rebound.
Key entities
- companyAlignment Healthcare
US-listed Medicare Advantage insurer.


